Because of the progress in diagnostic transplantation pathology interpretation of transplant biopsies is increasingly becoming an attractive field for general surgical pathologists. The book focuses on the pathology of transplantation in the following organs: kidney, liver, lungs, heart, pancreas and small intestine. An introductory section addresses common entities that may complicate all transplant recipients such as infections, post-transplant lymphoproliferative disease and graft versus host disease, followed by 6 sections with detailed manifestations of rejection in each organ. This comprehensive, well-illustrated book serves the needs and meets the requirements of pathologists in training and those practicing in centers with limited volume of transplant biopsies in daily practice.

Helen Liapis is Professor of Pathology and Immunology and Professor of Nephrology at Washington University School of Medicine in St. Louis, USA. She is an internationally acclaimed expert in kidney disease and transplantation, and is currently a member of the editorial boards of Pathology Research International and the International Journal of Urology and Nephrology and regular reviewer of numerous Nephrology and Pathology journals. Dr. Liapis is the author of 100 journal articles in the field, as well as a co-author in Heptinstall's Pathology of the Kidney, an atlas of renal pathology and editor or author in other renal pathology books. Hanlin Wang is Director of Gastrointestinal Pathology in the Department of Pathology and Laboratory Medicine at Cedars-Sinai Medical Center, Los Angeles, USA. He is the recipient of a number of awards and the author of more than 90 peer-reviewed scientific papers and numerous invited reviews and book chapters. Dr. Wang serves the editorial boards for several medical journals and is a reviewer for numerous scientific journals and grant agencies. His research interests include liver and gastrointestinal diseases.

1;Pathology of Solid Organ Transplantation;2 1.1;Copyright Page;3 1.2;Dedication;4 1.3;Preface;5 1.4;Contents;8 1.5;Part I Immunology, Clinical, and LaboratoryAspects of Organ Transplantation;10 1.5.1;1: Immunology of Organ Transplantation;11 1.5.1.1;1.1 Introduction;11 1.5.1.2;1.2 Basic Transplantation Immunology;11 1.5.1.2.1;1.2.1 Components of the Immune System;11 1.5.1.3;1.3 The Adaptive Alloimmune Response;11 1.5.1.3.1;1.3.1 Recognition of Alloantigen;12 1.5.1.3.2;1.3.2 Cellular Alloimmunity;12 1.5.1.3.3;1.3.3 Humoral Alloimmunity;13 1.5.1.3.4;1.3.4 Resolution of the Alloimmune Response;14 1.5.1.3.5;1.3.5 Transplant Tolerance;14 1.5.1.4;1.4 Organ Specific Effects and Clinical Applications of Transplant Immunology;15 1.5.1.5;References;15 1.5.2;2: Current Concepts of Immunosuppression and Side Effects;18 1.5.2.1;2.1 Introduction;18 1.5.2.2;2.2 Induction Drugs;18 1.5.2.3;2.3 OKT 3;19 1.5.2.3.1;2.3.1 Mechanism of Action;19 1.5.2.3.2;2.3.2 Efficacy;19 1.5.2.3.3;2.3.3 Side Effects;19 1.5.2.4;2.4 IL-2 Receptor Antagonists (Anti CD25 Antibodies);20 1.5.2.4.1;2.4.1 Mechanism;20 1.5.2.4.2;2.4.2 Dosage;20 1.5.2.4.3;2.4.3 Efficacy;20 1.5.2.4.4;2.4.4 Side Effects;21 1.5.2.5;2.5 Polyclonal Antibodies (Thymoglobulin and ATGAM);22 1.5.2.5.1;2.5.1 Mechanism of Action;22 1.5.2.5.2;2.5.2 Dosage;22 1.5.2.5.3;2.5.3 Clinical Efficacy;22 1.5.2.5.4;2.5.4 Side Effects;22 1.5.2.6;2.6 Alemtuzumab;23 1.5.2.6.1;2.6.1 Mechanism of Action;23 1.5.2.6.2;2.6.2 Dosage;23 1.5.2.6.3;2.6.3 Clinical Efficacy;23 1.5.2.6.4;2.6.4 Side Effects;23 1.5.2.7;2.7 Maintenance Drugs;24 1.5.2.7.1;2.7.1 Prednisone;24 1.5.2.7.1.1;2.7.1.1 Mechanism of Action;24 1.5.2.7.1.2;2.7.1.2 Dosage;24 1.5.2.7.1.3;2.7.1.3 Clinical Efficacy;24 1.5.2.7.1.4;2.7.1.4 Side Effects;25 1.5.2.7.2;2.7.2 Calcineurin Inhibitors;25 1.5.2.7.2.1;2.7.2.1 Mechanism of Action;25 1.5.2.7.2.2;2.7.2.2 Dosage;25 1.5.2.7.2.3;2.7.2.3 Clinical Efficacy;25 1.5.2.7.2.4;2.7.2.4 Side Effects;26 1.5.2.7.3;2.7.3 Mycophenolate;27 1.5.2.7.3.1;2.7.3.1 Mechanism of Action;27 1.5.2.7.3.2;2.7.3.2 Dosage;28 1.5.2.7.3.3;2.7.3.3 Clinical Efficacy;28 1.5.2.7.3.4;2.7.3.4 Side Effects;28 1.5.2.7.4;2.7.4 Rapamycin (Sirolimus);28 1.5.2.7.4.1;2.7.4.1 Mechanism of Action;28 1.5.2.7.4.2;2.7.4.2 Dosage;28 1.5.2.7.4.3;2.7.4.3 Clinical Efficacy;28 1.5.2.7.4.4;2.7.4.4 Side Effects;29 1.5.2.8;2.8 Newer Immunosuppressive Medications;30 1.5.2.8.1;2.8.1 Janus Kinase (JAK) 3 Inhibitors;30 1.5.2.9;2.9 AEB-071;30 1.5.2.9.1;2.9.1 LEA 29Y (Belatacept);30 1.5.2.10;2.10 Efalizumab;31 1.5.2.11;2.11 Summary;31 1.5.2.12;References;31 1.5.3;3: Clinical Aspects of Infection;38 1.5.3.1;3.1 Introduction;38 1.5.3.2;3.2 Infections and Timing of Transplant;38 1.5.3.2.1;3.2.1 Month 1;39 1.5.3.2.2;3.2.2 Months 2-6;39 1.5.3.2.3;3.2.3 Greater than 6 Months;39 1.5.3.3;3.3 Viral Infections;39 1.5.3.3.1;3.3.1 Cytomegalovirus;39 1.5.3.4;3.4 Epstein-Barr Virus (EBV) and Posttransplant Lymphoproliferative Disorders (PTLD);42 1.5.3.5;3.5 BK Virus and Nephropathy;45 1.5.3.6;3.6 Hepatitis C;48 1.5.3.7;3.7 Parvovirus B19;48 1.5.3.8;3.8 Fungal Infections;48 1.5.3.9;3.9 Pneumocystis Jiroveci (PCP);49 1.5.3.10;3.10 Summary;49 1.5.3.11;References;49 1.5.4;4: Clinical Evaluation of Alloantibodies in Solid Organ Transplantation;51 1.5.4.1;4.1 Introduction;51 1.5.4.2;4.2 Alloantibody Specificities;51 1.5.4.2.1;4.2.1 Alloantibodies Against HLA;51 1.5.4.2.2;4.2.2 ABO Blood Group Antibodies;53 1.5.4.2.3;4.2.3 MICA;53 1.5.4.2.4;4.2.4 Alloantibodies to Non-HLA Antigens;53 1.5.4.3;4.3 Clinical Testing for Alloantibodies;54 1.5.4.3.1;4.3.1 Cytotoxicity Crossmatch;54 1.5.4.3.2;4.3.2 Solid Phase Immunoassays for Detection of Alloantibodies;56 1.5.4.3.3;4.3.3 Virtual Crossmatching and Donor Selection;56 1.5.4.3.4;4.3.4 Posttransplant Testing;57 1.5.4.3.5;4.3.5 Immunologic Accommodation;58 1.5.4.4;References;58 1.5.5;5: Frontiers in Organ Transplantation;63 1.5.5.1;5.1 Introduction;63 1.5.5.2;5.2 Growing New Kidneys;63 1.5.5.2.1;5.2.1 Immune Response to Fetal Kidney Transplants;64 1.5.5.2